ANNOVIS BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.23 USD | -5.94% |
|
-1.56% | -55.99% |
Presenter SpeechMaria MacCecchini (Executives)Thank you for being with me today, and thank you...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimerâs disease (AD), Parkinsonâs disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.
Calendar
2024-08-04
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
8.23
USD
Average target price
35.25
USD
Spread / Average Target
+328.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -55.99% | 91.94M | |
| +8.63% | 114B | |
| +13.17% | 107B | |
| -12.76% | 22.22B | |
| -3.99% | 21.28B | |
| -7.19% | 17.51B | |
| -39.93% | 17.17B | |
| +6.67% | 14.14B | |
| +33.90% | 12.2B | |
| -28.60% | 7.83B |
- Stock Market
- Equities
- ANVS Stock
- News Annovis Bio, Inc.
- Transcript : Annovis Bio, Inc. - Special Call